Graduate School of Medicine, Keio University, Tokyo 160-8582, Japan.
Omori Red Cross Hospital, Tokyo 143-8527, Japan.
Medicina (Kaunas). 2022 Jun 16;58(6):815. doi: 10.3390/medicina58060815.
Empagliflozin is a sodium-glucose cotransporter-2 inhibitor widely used in the treatment of diabetes mellitus and heart failure. Our case study involved a 68-year-old patient who was admitted to the hospital because of a cerebral infarction. The patient was simultaneously diagnosed with diabetes mellitus and heart failure, for which empagliflozin was initiated. However, food and fluid intake were reduced due to poor appetite. In addition to the side effects of empagliflozin, the patient developed severe dehydration and cardiac arrest. Careful assessment of dehydration and preventive water intake is recommended in elderly patients and those with neurological deficits, especially when receiving empagliflozin.
恩格列净是一种钠-葡萄糖协同转运蛋白 2 抑制剂，广泛用于治疗糖尿病和心力衰竭。我们的病例研究涉及一名 68 岁的患者，他因脑梗死住院。该患者同时被诊断患有糖尿病和心力衰竭，开始使用恩格列净治疗。然而，由于食欲不佳，食物和液体摄入减少。除了恩格列净的副作用外，该患者还出现严重脱水和心脏骤停。建议在老年患者和有神经功能缺损的患者中，特别是在接受恩格列净治疗时，仔细评估脱水情况并预防摄入水分。
